Clinical characteristics, follow-up, and outcomes of all EXT1/EXT2-positive and EXT1/EXT2-negative LMN with proliferative features (class 5 with class 3/4 LN)
| Variable | EXT1/EXT2-Positive LMN, n=16/64 (25.0%) | EXT1/EXT2-Negative LMN, n=31/96 (32.3%) | P Valuea |
|---|---|---|---|
| Age at presentation, median (IQR), yr | 32 (25–43) | 33 (28–47) | 0.39 |
| Female, n (%) | 15 (93.8) | 22 (71.0) | 0.07 |
| SCr at presentation, median (IQR), mg/dl | 1.0 (0.8–2.0), n=15 | 1.20 (0.8–2.3), n=31 | 0.35 |
| Proteinuria at presentation, median (IQR), g/24 h | 6.6 (1.5–7.9), n=13 | 3.7 (1.7–6.5), n=25 | 0.48 |
| Proteinuria at presentation ≥3.5/d, n (%) | 9 (69.2), n=13 | 15 (60), n=25 | 0.58 |
| Hematuria, n (%) | 4 (25.0) | 13 (41.9) | 0.25 |
| Other autoimmune diseases, n (%) | 5 (31.3) | 7 (22.6) | 0.52 |
| Sclerosed glomeruli, median (IQR), % | 4.6 (0.0–12.5) | 20.0 (3.22–27.8) | 0.01 |
| IFTA, median (IQR), % | 0.0 (0.0–8.75) | 10.0 (5.0–20.0) | 0.003 |
| SCr at end of follow-up, median (IQR), mg/dl | 0.90 (0.8–1.5), n=13 | 1.30 (0.70–1.9), n=20 | 0.32 |
| Proteinuria at end of follow-up, median (IQR), g/24 h | 0.60 (0.20–1.25), n=10 | 1.5 (0.30–3.40), n=15 | 0.12 |
| Proteinuria at end of follow-up ≥3.5/d, n (%) | 0 (0.0), n=10 | 3 (20.0), n=15 | 0.13 |
| ESKD, n (%) | 0 (0.0) | 7 (22.6) | 0.04 |
| Death, n (%) | 0 (0.0) | 6 (19.4) | 0.06 |
| Time of follow-up, median (IQR), mo | 48.6 (43.0–76.3) | 43.4 (27.1–77.9) | 0.27 |
↵a P<0.05 is considered significant.